Autonomix Medical (NASDAQ:AMIX – Get Free Report) and NeuroPace (NASDAQ:NPCE – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, valuation, profitability and dividends.
Risk & Volatility
Autonomix Medical has a beta of -1.82, suggesting that its stock price is 282% less volatile than the S&P 500. Comparatively, NeuroPace has a beta of 1.92, suggesting that its stock price is 92% more volatile than the S&P 500.
Insider and Institutional Ownership
10.8% of Autonomix Medical shares are held by institutional investors. Comparatively, 78.8% of NeuroPace shares are held by institutional investors. 6.2% of Autonomix Medical shares are held by company insiders. Comparatively, 20.5% of NeuroPace shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Autonomix Medical | N/A | -228.82% | -186.65% |
| NeuroPace | -21.67% | -108.20% | -18.50% |
Valuation and Earnings
This table compares Autonomix Medical and NeuroPace”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Autonomix Medical | N/A | N/A | -$11.41 million | ($3.55) | -0.11 |
| NeuroPace | $99.99 million | 5.77 | -$21.47 million | ($0.65) | -26.03 |
Autonomix Medical has higher earnings, but lower revenue than NeuroPace. NeuroPace is trading at a lower price-to-earnings ratio than Autonomix Medical, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of recent recommendations and price targets for Autonomix Medical and NeuroPace, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Autonomix Medical | 1 | 1 | 1 | 0 | 2.00 |
| NeuroPace | 1 | 1 | 4 | 2 | 2.88 |
Autonomix Medical presently has a consensus target price of $2.00, indicating a potential upside of 401.25%. NeuroPace has a consensus target price of $18.83, indicating a potential upside of 11.31%. Given Autonomix Medical’s higher possible upside, analysts clearly believe Autonomix Medical is more favorable than NeuroPace.
Summary
NeuroPace beats Autonomix Medical on 10 of the 14 factors compared between the two stocks.
About Autonomix Medical
Autonomix Medical, Inc., a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.
About NeuroPace
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
Receive News & Ratings for Autonomix Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autonomix Medical and related companies with MarketBeat.com's FREE daily email newsletter.
